-

10:30:14 PM

NVAX Stock News

NVAX - Novavax, Inc.

11/29/22 8:48 AM

Nasdaq : NVAX

covid-19high short

World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use

RHEA-AI

negative

11/18/22 8:08 AM

Nasdaq : NVAX

covid-19high short

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Health Canada has granted expanded authorization for Nuvaxovid™

RHEA-AI

negative

11/14/22 4:02 PM

Nasdaq : NVAX

conferenceshigh short

Novavax to Participate in Jefferies London Healthcare Conference

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the Jefferies London Healthcare Conference.

RHEA-AI

neutral

11/09/22 9:19 AM

Nasdaq : NVAX

covid-19high short

Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the

RHEA-AI

negative

11/08/22 4:02 PM

Nasdaq : NVAX

earningshigh short

Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights

Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to date Authorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and

RHEA-AI

neutral

11/08/22 8:00 AM

Nasdaq : NVAX

clinical trialcovid-19high short

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains The trial showed no benefit for a bivalent vaccine utilizing

RHEA-AI

neutral

11/01/22 4:30 PM

Nasdaq : NVAX

managementhigh short

Novavax Appoints Rick Rodgers to Board of Directors

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the appointment of Richard Rodgers, MBA to its board as an independent

RHEA-AI

neutral

11/01/22 4:02 PM

Nasdaq : NVAX

conferencesearningshigh short

Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational

RHEA-AI

neutral

10/20/22 2:15 PM

Nasdaq : NVAX

high short

Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

New Phase 3 PREVENT-19 data reinforce the Novavax COVID-19 vaccine's benefits as an adult booster in both younger and older adults, and with varying time intervals for the booster dose Phase 1/2 trial data show COVID-19-Influenza Combination vaccine candidate induced antibody and T-cell responses

RHEA-AI

neutral

10/19/22 11:03 AM

Nasdaq : NVAX

covid-19high short

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received

RHEA-AI

negative

1 2 3 4 5 6 7 8 9 10 Next

NVAX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.novavax.com
CeoStanley Erck
Security nameNovavax, Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees791
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address21 Firstfield Rd
StateMaryland
CityGaithersburg
Zip20878-1757
CountryUS
Phone12402682000

About Novavax, Inc.

Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.